Yersinia Enterocolitica


Practice Essentials

Yersinia enterocolitica (see the image below) is a bacterial species in the family Enterobacteriaceae that most often causes enterocolitis, acute diarrhea, terminal ileitis, mesenteric lymphadenitis, and pseudoappendicitis but, if it spreads systemically, can also result in fatal sepsis.[1]

View Image

Gram stain of Yersinia enterocolitica.

Signs and symptoms

Symptoms of Y enterocolitica infection typically include the following:

The patient may also develop erythema nodosum, which manifests as painful, raised red or purple lesions, mainly on the patient’s legs and trunk. Lesions appear 2-20 days after the onset of fever and abdominal pain and resolve spontaneously in most cases in about a month.

See Clinical Presentation for more detail.


The following tests can be used in the diagnosis of Y enterocolitica infection:

See Workup for more detail.


Care in patients with Y enterocolitica infection is primarily supportive, with good nutrition and hydration being mainstays of treatment.[4]

First-line drugs used against the bacterium include the following agents:

See Treatment and Medication for more detail.


Yersinia enterocolitica is a pleomorphic, gram-negative bacillus that belongs to the family Enterobacteriaceae. As a human pathogen, Y enterocolitica is most frequently associated with enterocolitis, acute diarrhea, terminal ileitis, mesenteric lymphadenitis, and pseudoappendicitis,[1] with the spectrum of disease ranging from asymptomatic to life-threatening sepsis, especially in infants. The bacterium was first reported by Mclver and Picke, in 1934.[5] Schleifstein and Coleman provided the first recognized description of 5 human isolates of Y enterocolitica, in 1939. (See Prognosis and Clinical Presentation.)[6]

In several countries, Y enterocolitica has eclipsed Shigella species and approaches Salmonella and Campylobacter species as the predominant cause of acute bacterial gastroenteritis. Y enterocolitica most commonly affects young individuals (approximately 75% of patients with Y enterocolitica infection are aged 5-15 years), but whether this represents an increased susceptibility or a greater likelihood of developing symptomatic illness is unclear. Most cases of Y enterocolitica infection are sporadic, but reports have documented large outbreaks centered on a single contaminated source. (See Epidemiology.)

Human yersiniosis is attributed to contaminated pork, milk, water, and tofu consumption, as well as to blood transfusion. Infected individuals may shed Y enterocolitica in stools for 90 days after the symptom resolution, suggesting that early detection of Y enterocolitica from diarrheal stool samples is critical in preventing its transmission and an eventual outbreak. (See Pathophysiology, Etiology, Clinical Presentation, and Workup.)[7, 8]


Y enterocolitica is classified according to various distinct biochemical and serologic reactions. Based on biochemical characteristics, 6 biotypes of the bacterium have been described. Biotypes 2, 3, and 4 are most common in humans. The serotyping is based on O and H antigens. More than 60 serotypes of Y enterocolitica have been described. The serotypes most clearly pathogenic to humans include O:3, O:5,27, O:8, O:9, and O:13.

H-antigen typing can be a valuable supplement to O-antigen typing and biochemical characterization in epidemiologic investigations. Accurate identification of pathogenic strains requires consideration of both the biotype and the serotype because some strains can contain multiple cross-reacting O antigens.


Y enterocolitica is non–lactose-fermenting, glucose-fermenting, and oxidase-negative facultative anaerobe that is motile at 25°C and nonmotile at 37°C. Most, but not all, Y enterocolitica isolates reduce nitrates. The presence of bile salts in the medium prevents the organism from fermenting lactose. Colonies of Y enterocolitica do not produce hydrogen sulfide in triple sugar iron medium, but the organism is urease positive.

Patient education

Educate patients and individuals at risk for infection about appropriate hygiene methods and signs or symptoms of infection. Encourage public awareness of outbreaks, modes of transmission, and ways to prevent transmission.


As with other members of the genus Yersinia, Y enterocolitica is an invasive organism that appears to cause disease by tissue destruction. Researchers have elucidated several potential pathogenic properties, including chromosomally mediated effects (eg, attachment to tissue culture, production of enterotoxin) and plasmid-mediated mechanisms (eg, production of Vw antigens, calcium dependency for growth, autoagglutination).

Invasion and colonization

Invasion of human epithelial cells and penetration of the mucosa occurs in the ileum, followed by multiplication in Peyer patches. A 103-kd protein, known as invasin and determined by the INV gene, mediates bacterial invasion. The best-defined pathway is through the action of invasin.[9]

As a foodborne pathogen, Y enterocolitica can efficiently colonize and induce disease in the small intestine. Following ingestion, the bacteria colonize the lumen and invade the epithelial lining of the small intestine, resulting in the colonization of the underlying lymphoid tissues known as Peyer patches. A direct lymphatic link between the Peyer patches and mesenteric lymph nodes may result in bacterial dissemination to these sites, resulting in mesenteric lymphadenitis or systemic infection.

Dissemination to extraintestinal sites, such as the spleen, is hypothesized to occur via 2 main mechanisms: (1) colonization of the Peyer patches, which can then be used as a staging ground for spread into the blood and/or lymph, ultimately resulting in the appearance of bacteria in other tissues, and (2) bypass of the Peyer patches, with Y enterocolitica going straight to systemic colonization. The possibilities of additional avenues for dissemination have yet to be excluded.

Y enterocolitica colonization of the intestinal lymphoid tissues requires transmigration of the bacteria from the intestinal lumen across an epithelial tissue barrier. Antigen-sampling intestinal epithelial cells known as M cells are thought to be critical for this transmigratory process. The epithelium overlying the Peyer patches has a high concentration of M cells (although these cells have also been identified throughout the non–Peyer patch areas of the small intestine).

Y enterocolitica and the related pathogen Y pseudotuberculosis produce at least 3 invasion proteins, Ail, YadA, and the aforementioned invasin, which could potentially promote adherence to and invasion of M cells. Invasin, the principle invasion factor of Y enterocolitica and Y pseudotuberculosis, binds to ß1 -chain integrin receptors with high affinity, promoting internalization. These receptors are found at high levels on the luminal side of M cells but not on the luminal side of enterocytes.[10]


The enterotoxin produced by Y enterocolitica is similar to that produced by the heat-stable Escherichia coli; however, it likely plays a minor role in causing disease, as diarrheal syndromes have been observed in the absence of enterotoxin production. In addition, the toxin does not appear to be produced at temperatures higher than 30°C. The plasmid-mediated outer membrane antigens are associated with bacterial resistance to opsonization and neutrophil phagocytosis.

Iron and pathogenicity

One unique property of Y enterocolitica is its inability to chelate iron, which is an essential growth factor for most bacteria and is obtained through the production of chelators known as siderophores. Y enterocolitica does not produce siderophores but can utilize siderophores produced by other bacteria (eg, desferrioxamine E produced by Streptomyces pilosus).

Iron overload substantially increases the pathogenicity of Y enterocolitica, perhaps through attenuation of the bactericidal activity of the serum. Researchers observe differences in the iron requirements of different serotypes of the organism; such differences may explain, in part, the varying degrees of virulence among serotypes.


After an incubation period of 4-7 days, infection may result in mucosal ulceration (usually in the terminal ileum and rarely in the ascending colon), necrotic lesions in Peyer patches, and mesenteric lymph node enlargement. See the image below.

View Image

Yersinia enterocolitis in a 45-year-old white woman who presented with chronic diarrhea.

In severe cases, bowel necrosis may occur, as a result of mesenteric vessel thrombosis.[11] Focal abscesses may occur. In persons with human leukocyte antigen (HLA)–B27, reactive arthritis is not uncommon, possibly because of the molecular similarity between HLA-B27 antigen and Yersinia antigens. The pathogenesis of Yersinia -associated erythema nodosum is unknown.[12, 13]


Human clinical Y enterocolitica infections ensue after ingestion of the microorganisms in contaminated food or water or by direct inoculation through blood transfusion.

Y enterocolitica is potentially transmitted by contaminated unpasteurized milk and milk products, raw pork, tofu, meats, oysters, and fish.[14, 15] Outbreaks have been associated with raw vegetables; the surface of vegetables can become contaminated with pathogenic microorganisms through contact with soil, irrigation water, fertilizers, equipment, humans, and animals.

Pasteurized milk and dairy products can also cause outbreaks because Yersinia can proliferate at refrigerated temperatures.[16, 17]

Animal reservoirs of Y enterocolitica include swine (principle reservoir), dogs, cats, cows, sheep, goats, rodents, foxes, porcupines, and birds.

Reports of person-to-person spread are conflicting and are generally not observed in large outbreaks. Transmission via blood products has occurred, however, and infection can be transmitted from mother to newborn infant. Fecal-oral transmission among humans has not been proven.[18, 19] .


Occurrence in the United States

Yersiniosis is rare in the absence of a breakdown in food-processing techniques. The Centers for Disease Control and Prevention (CDC) estimates that 1 culture-confirmed Y enterocolitica infection per 100,000 persons is found annually.[20] The bacterium has been isolated in 1.4-2.8% of stools of children with diarrhea.

For 2010, the CDC’s Foodborne Diseases Active Surveillance Network (FoodNet), using surveillance data from 10 US sites, preliminarily identified a total of 19,089 laboratory-confirmed cases of infection caused by bacterial pathogens that are commonly transmitted through food. The number of cases and incidence per 100,000 population were reported as follows[21] :

In the United States, Yersinia enterocolitica accounts for approximately 5% of bacterial enteric infections among children younger than 5 years, according to a 2012 study by Scallan et al. The investigators found this to be a greater incidence than that for the enterohemorrhagic E coli strain O157 (3%), but a lower incidence than those for nontyphoidal Salmonella (42%), Campylobacter (28%), and Shigella (21%).[22]

Scallan et al estimated that the 5 pathogens together cause more than 290,000 illnesses annually in children under 5 years.

Y enterocolitica infection is more common in cooler climates, and its prevalence peaks from November to January.[23]

International statistics

Y enterocolitica has been isolated in patients in many countries worldwide, but the infection appears to occur predominantly in cooler climates, being much more common in northern Europe, Scandinavia, and Japan. Most isolates reported from Canada and Europe are O:3 and O:9 serotypes.[24] The O:3 serotype is also common in Japan. Isolation of Y enterocolitica in developing countries is uncommon.[25]

Race- and age-related demographics

Higher incidence of Y enterocolitica infection has been observed among black infants in the United States.[26]

Reports document symptomatic Y enterocolitica infection most commonly in younger age groups. A sample collection from 1988-1991 showed that 77.6% of infections occurred in children aged 12 months and younger, making Y enterocolitica the second most common cause of bacterial gastrointestinal infection in children.[22, 27, 28]

Clinical manifestations of Y enterocolitica infection exhibit some age-dependent predilections, with reactive arthritis and erythema nodosum being more common in older patients. Older patients with more debility are more likely to develop bacteremia than are younger, healthier patients.


Yersiniosis is usually either self-limited or is responsive to therapy; however, reinfection is possible. Most patients with Y enterocolitica infection are symptomatic; however, asymptomatic carriage may occur. Death is uncommon, but patients with significant comorbidities are at risk for Y enterocolitica bacteremia, which carries a case fatality rate of 34-50%.

A national, registry-based study of 52,121 patients in Denmark reported estimates for the risk of developing severe, hospitalization-requiring complications and long-term sequelae up to 1 year after infection with 5 common bacterial gastrointestinal pathogens. Of the 3922 cases of Y enterocolitica infection reported, 368 required hospitalization.[29]

A report from the CDC stated that in 2010 (preliminary data), of 159 Yersinia infections in the United States, 52 required hospitalization and 1 resulted in death.[21]

Various manifestations of Y enterocolitica infection have been reported, including the following[30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42] :

Iron is an essential growth factor for the organism, and iron overload (eg, chronic hemolysis, hereditary hemochromatosis) is associated with an increased risk of systemic disease. Deferoxamine therapy also increases susceptibility to Y enterocolitica disease.

History and Physical Examination

The usual presentation of Y enterocolitica infection includes diarrhea (the most common clinical manifestation of this infection), low-grade fever, and abdominal pain lasting 1-3 weeks. Diarrhea may be bloody in severe cases. Vomiting is present in approximately 15-40% of cases.

The existence of extraintestinal symptoms after a gastrointestinal illness may also indicate the possibility of yersiniosis.


Enterocolitis, the most common presentation of Y enterocolitica, occurs primarily in young children, with a mean age of 24 months. The incubation period is 4-6 days, typically with a range of 1-14 days.

Prodromal symptoms of listlessness, anorexia, and headache may be present. Such symptoms are followed by watery, mucoid diarrhea (78-96%); fever (43-47%); colicky abdominal pain (22-84%); bloody stools (< 10%); and white blood cells (WBCs) in the stool (25%). The diarrhea generally has a duration of 1 day to 3 weeks.

Most cases are self-limited. However, concomitant bacteremia may occur in 20-30% of infants younger than 3 months.

Complications of enterocolitis include appendicitis,[41] diffuse ulceration and inflammation of the small intestine and colon, peritonitis,[43, 44] meningitis, intussusception,[45] and cholangitis.

Mesenteric adenitis, mesenteric ileitis, and acute pseudoappendicitis

These manifestations are characterized by the following symptoms (although nausea, vomiting, diarrhea, and aphthous ulcers of the mouth can also occur):

Pseudoappendicitis syndrome is more common in older children and young adults.[46] Patients with Y enterocolitica infection often undergo appendectomy; several Scandinavian studies suggested a prevalence rate of 3.8-5.6% for infection with Y enterocolitica in patients with suspected appendicitis.

Analysis of several common-source outbreaks in the United States found that 10% of 444 patients with symptomatic, undiagnosed Y enterocolitica infection underwent laparotomy for suspected appendicitis.

Reactive arthritis

This is associated with HLA-B27 (found in approximately 80% of affected patients). Most commonly reported in Scandinavia, polyarticular arthritis can occur after Y enterocolitica infection. Joint symptoms, which occur in approximately 2% of patients, typically arise 1-2 weeks after gastrointestinal illness.[13]

The large joints of the lower extremities are involved most commonly, and symptoms usually persist for 1-4 months, although reports document prolonged syndromes.

Myocarditis and glomerulonephritis

These are other postinfection sequelae associated with the HLA-B27.[47]

Erythema nodosum

This manifests as painful, raised red or purple lesions, mainly on the patient’s legs and trunk. Lesions appear 2-20 days after the onset of fever and abdominal pain and resolve spontaneously in most cases in about a month. The female-to-male ratio of erythema nodosum is 2:1, and it is more common in adults than in children.


In this, a bacteremic spread to extraintestinal sites occurs, resulting in critical illness. Y enterocolitica septicemia is reported most commonly in patients who have predisposing conditions, including alcoholism, diabetes mellitus, or an underlying immune defect.

Patients with iron overload conditions and those who are undergoing treatment with deferoxamine are also at an increased risk for septicemia, secondary to the effect of iron on the virulence of the bacteria.[14]

In addition, Y enterocolitica septicemia is usually reported in patients with a hematologic disease, such as thalassemia, sickle cell disease, or hemochromatosis.[14, 48, 49, 50] Elderly patients and those who are malnourished are also at increased risk of developing septicemia.

Metastatic infections following Y enterocolitica septicemia include focal abscesses in the liver, kidneys, spleen, and lungs. Cutaneous manifestations include cellulitis, pyomyositis, pustules, and bullous lesions. Pneumonia, meningitis, panophthalmitis, endocarditis, infected mycotic aneurysm, and osteomyelitis may also occur.[47]

Approach Considerations

The following tests can be used in the diagnosis of Y enterocolitica infection (see the image below):

Stool Culture

Stool samples tested for leukocytes usually produce positive results, but Y enterocolitica is difficult to distinguish from other invasive pathogens. Stool samples from infected patients should be handled carefully to avoid infecting others.

When Y enterocolitica infection is suspected, instruct the microbiology laboratory to use cefsulodin-Irgasan-novobiocin (CIN) agar, which is a differential selective medium with increased yield for Y enterocolitica. It requires 18-20 hours of incubation at 25°C to create unique colony morphology, representing 0.5- to 1-mm colonies with a red "bull's-eye" and a clear border. Use of this media allows differentiation between Y enterocolitica and Y enterocolitica– like isolates.

When using conventional enteric media, MacConkey agar incubated at 25°C for 48 hours produces the best results.[51]

Recovery of organisms from otherwise sterile samples, such as blood, cerebrospinal fluid (CSF), and lymph node tissue, is usually faster than recovery from stool samples. Isolation of Y enterocolitica from stool is hampered by slow growth and overgrowth of normal flora.


Serodiagnosis is possible with various methods, including tube agglutination, enzyme-linked immunosorbent assays, and radioimmunoassays. However, carefully interpret the serotest results for Y enterocolitica infection if a positive stool culture result is absent. Cross-reactions with other organisms can occur—including with Brucella, Morganella, and Salmonella —and a background seroprevalence rate among different populations may confound the diagnosis by acting as a false-positive result.

Agglutinin titers typically increase 1-2 weeks after infection and peak at 1:200. However, elevated levels can be found for years after infection, which also limits the usefulness of serodiagnosis.

DNA Microarray

Advanced experimental techniques for diagnosis of Y enterocolitica infection include polymerase chain reaction (PCR) assay, immunohistochemical staining, and DNA microarray. Diagnostic DNA microarray for pathogenetic organisms is a comparatively new technique that is used to identify multiple genes from different kinds of pathogens, allowing it to be used to detect different species, biotypes, and/or toxins of pathogenic organisms in the same specimens. This is the major advantage over the conventional PCR assay technique, which is used to identify only 1 gene from a hybridization. DNA microarray is also more sensitive and accurate than the multiplex PCR.[52]


Typically, in patients with Y enterocolitica infection, the cecum contains aphthoid lesions and the terminal ileum has small, round elevations and ulcers (as seen in the image below). An exudate may be present. The left side of the colon is typically unaffected, but case reports have described left-sided colitis with serotype O:8.

View Image

Yersinia enterocolitis in a 45-year-old white woman who presented with chronic diarrhea.

Histologic Findings

Histologic findings in Y enterocolitica infection are consistent with acute and chronic inflammation. Yersiniosis does not produce unique histologic findings. Epithelial cell granulomas with suppuration of the centers of the granulomas (central microabscesses) have been reported. These granulomas were composed of numerous histiocytes with or without epithelioid cell features, along with scattered small T-lymphocytes and plasmacytoid monocytes.[53]

Approach Considerations

Care in patients with Y enterocolitica infection is primarily supportive, with good nutrition and hydration being mainstays of treatment.[4]

First-line drugs used against the bacterium include aminoglycosides and trimethoprim-sulfamethoxazole (TMP-SMZ). Other effective drugs include third-generation cephalosporins, tetracyclines (not recommended in children < 8 y), and fluoroquinolones (not approved for use in children < 18 y).

In the event of an acute outbreak of Y enterocolitica, attempt to isolate persons who have been in contact with the index patient.

Surgical therapy

Abscesses may require surgical drainage. Surgical exploration may be warranted if appendicitis cannot be safely ruled out.

Laparotomy findings in Y enterocolitica infection usually include mesenteric lymphadenitis and terminal ileitis, with a healthy appendix.


The diagnosis and management of yersiniosis do not require specific consultations. However, consultation with an infectious diseases specialist or gastroenterologist may be useful. Consultation with a rheumatologist may be helpful in cases of erythema nodosum or reactive arthritis.

Antibiotic Therapy

The value of antibiotic therapy in uncomplicated acute diarrhea has not been established. Diarrhea should be managed with fluid and electrolyte replacement. Avoid antimotility medications, which could lead to bacteremia.

In cases of severe enterocolitis, antibiotics have shown some benefit in terms of shortening the duration of illness. Patient populations who should be considered for empiric antibiotic therapy include the following:

Antibiotic treatment should be used in patients with bacteremia with extraintestinal manifestations. They should be used in cases of primary extraintestinal disorders, such as the following:

Inpatient Care

Admit patients with Y enterocolitica infection who have evidence of severe dehydration, malnourishment, or septicemia.

Patients with conditions that place them at risk for Y enterocolitica septicemia, including the following, should be monitored closely and admitted for supportive measures and antibiotic therapy at the first sign of disseminated disease:

Deterrence and Prevention

The following steps can be taken to prevent the spread of Y enterocolitica infection:

Medication Summary

Treatment of Y enterocolitica infection is usually supportive and directed at maintaining euvolemia. Antibiotics may be used in some cases. Septicemia carries a high mortality rate and should therefore be treated with antibiotics. Uncomplicated cases Y enterocolitica diarrhea usually resolve on their own without antibiotic treatment. However, in more severe or complicated infections, antibiotics may be useful.

Y enterocolitica is usually susceptible in vitro to aminoglycosides, chloramphenicol, tetracycline, trimethoprim-sulfamethoxazole (TMP-SMZ), piperacillin, ciprofloxacin, and third-generation cephalosporins. Isolates are often resistant to penicillin, ampicillin, and first-generation cephalosporins, as the organism often produces beta-lactamase. Clinical failure with cefotaxime has been reported.[54] Resistance to macrolides and fluoroquinolones is also sporadically reported.[55]

Clinically, Y enterocolitica infection responds well to aminoglycosides, TMP-SMZ, ciprofloxacin, and doxycycline.

Antimotility agents are contraindicated in the treatment of Y enterocolitica infection because of the increased risk of invasion.

Ciprofloxacin (Cipro)

Clinical Context:  The bactericidal agent ciprofloxacin is a second-generation quinolone. It acts by interfering with DNA gyrase, by inhibiting the relaxation of supercoiled DNA, and by promoting the breakage of double-stranded DNA. Ciprofloxacin is highly active against gram-negative and gram-positive organisms.

Trimethoprim and sulfamethoxazole (Bactrim, Bactrim DS, Septra DS)

Clinical Context:  Trimethoprim and sulfamethoxazole (Bactrim, Bactrim DS, Septra DS)

The combination antibiotic TMP-SMZ inhibits bacterial growth by inhibiting the synthesis of dihydrofolic acid. It is not helpful in cases of uncomplicated gastroenteritis.

Ceftriaxone (Rocephin)

Clinical Context:  Ceftriaxone is a third-generation cephalosporin with gram-negative activity.


Clinical Context:  Gentamicin is an aminoglycoside that is bactericidal for susceptible gram-negative organisms. This agent is not helpful for uncomplicated gastroenteritis.

Cefotaxime (Claforan)

Clinical Context:  Cefotaxime is a third-generation cephalosporin with a gram-negative spectrum. It has lower efficacy against gram-positive organisms. This agent is not helpful for uncomplicated gastroenteritis.


Clinical Context:  Tetracycline treats gram-positive and gram-negative organisms, as well as mycoplasmal, chlamydial, and rickettsial infections. It inhibits bacterial protein synthesis by binding with the 30S and possibly 50S ribosomal subunit(s).


Clinical Context:  Chloramphenicol binds to 50S bacterial-ribosomal subunits and inhibits bacterial growth by inhibiting protein synthesis. It is effective against gram-negative and gram-positive bacteria.

Piperacillin and tazobactam sodium (Zosyn)

Clinical Context:  This drug combination consists of an antipseudomonal penicillin plus a beta-lactamase inhibitor. It inhibits the biosynthesis of cell wall mucopeptide and is effective during the active multiplication stage.

Class Summary

The value of antibiotic therapy in uncomplicated acute colitis and mesenteric adenitis is not established. Antibiotic treatment may be required in patients with septicemia, with focal extraintestinal manifestations, and in immunocompromised patients with enterocolitis.

Imipenem/cilastatin (Primaxin)

Clinical Context:  In vitro susceptibility to imipenem has been reported.


Zartash Zafar Khan, MD, FACP, Infectious Disease Consultant

Disclosure: Nothing to disclose.


Daniel R Bronfin, MD, Clinical Professor of Pediatrics, Tulane University School of Medicine; Vice Chairman of Pediatrics, Ochsner Children's Health Center

Disclosure: Nothing to disclose.

Michelle R Salvaggio, MD, FACP, Assistant Professor, Department of Internal Medicine, Section of Infectious Diseases, University of Oklahoma College of Medicine; Medical Director of Infectious Diseases Institute, Director, Clinical Trials Unit, Director, Ryan White Programs, Department of Medicine, University of Oklahoma Health Sciences Center; Attending Physician, Infectious Diseases Consultation Service, Infectious Diseases Institute, OU Medical Center

Disclosure: Received honoraria from Merck for speaking and teaching.

Chief Editor

Mark R Wallace, MD, FACP, FIDSA, Infectious Disease Physician, Skagit Valley Hospital, Skagit Regional Health

Disclosure: Nothing to disclose.


Daniel R Bronfin, MD Head, General Academic Pediatrics, Ochsner Children's Health Center

Daniel R Bronfin, MD is a member of the following medical societies: American Academy of Pediatrics and American Cleft Palate/Craniofacial Association

Disclosure: Nothing to disclose.

Richard B Brown, MD, FACP Chief, Division of Infectious Diseases, Baystate Medical Center; Professor, Department of Internal Medicine, Tufts University School of Medicine

Richard B Brown, MD, FACP is a member of the following medical societies: Alpha Omega Alpha, American College of Chest Physicians, American College of Physicians, American Medical Association, American Society for Microbiology, Infectious Diseases Society of America, and Massachusetts Medical Society

Disclosure: Nothing to disclose.

Brooks D Cash, MD, FACP Director of Clinical Research, Assistant Professor of Medicine, Gastroenterology, National Naval Medical Center

Disclosure: Nothing to disclose.

Joseph Domachowske, MD Professor of Pediatrics, Microbiology and Immunology, Department of Pediatrics, Division of Infectious Diseases, State University of New York Upstate Medical University

Joseph Domachowske, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics, American Society for Microbiology, Infectious Diseases Society of America, Pediatric Infectious Diseases Society, and Phi Beta Kappa

Disclosure: Nothing to disclose.

Thomas E Herchline, MD Professor of Medicine, Wright State University, Boonshoft School of Medicine; Medical Director, Public Health, Dayton and Montgomery County, Ohio

Thomas E Herchline, MD is a member of the following medical societies: Alpha Omega Alpha, Infectious Diseases Society of America, and Infectious Diseases Society of Ohio

Disclosure: Nothing to disclose.

Mark H Johnston, MD Associate Professor of Medicine, Uniformed Services University of the Health Sciences; Consulting Staff, Lancaster Gastroenterology, Inc

Mark H Johnston, MD is a member of the following medical societies: American College of Gastroenterology, American College of Physicians, American Gastroenterological Association, and Christian Medical & Dental Society

Disclosure: Nothing to disclose.

Leonard R Krilov, MD Chief of Pediatric Infectious Diseases and International Adoption, Vice Chair, Department of Pediatrics, Professor of Pediatrics, Winthrop University Hospital

Leonard R Krilov, MD is a member of the following medical societies: American Academy of Pediatrics, American Pediatric Society, Infectious Diseases Society of America, Pediatric Infectious Diseases Society, and Society for Pediatric Research

Disclosure: Medimmune Grant/research funds Cliinical trials; Medimmune Honoraria Speaking and teaching; Medimmune Consulting fee Consulting

Gregory J Martin, MD Director, Infectious Diseases Clinical Research Program (IDCRP) Associate Professor of Medicine, Uniformed Services University, Bethesda, MD

Gregory J Martin, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, American Society of Tropical Medicine and Hygiene, and Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Swetha G Pinninti, MD Fellow in Pediatric Infectious Diseases, Department of Pediatrics, University of Alabama at Birmingham School of Medicine

Swetha G Pinninti, MD is a member of the following medical societies: American Academy of Pediatrics, Infectious Diseases Society of America, and Pediatric Infectious Diseases Society

Disclosure: Nothing to disclose.

Russell W Steele, MD Head, Division of Pediatric Infectious Diseases, Ochsner Children's Health Center; Clinical Professor, Department of Pediatrics, Tulane University School of Medicine

Russell W Steele, MD is a member of the following medical societies: American Academy of Pediatrics, American Association of Immunologists, American Pediatric Society, American Society for Microbiology, Infectious Diseases Society of America, Louisiana State Medical Society, Pediatric Infectious Diseases Society, Society for Pediatric Research, and Southern Medical Association

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.


  1. Bercovier H, Brenner DJ, Ursing J, Steigerwalt AG, Fanning GR, Alonso JM, et al. Characterization of Yersinia enterocolitica sensu stricto. Current Microbiology. 1980. 4:201-6.
  2. Zheng H, Wang J, Sun Y, Jiang B. Clinical isolation and characterization of Yersinia enterocolitica in China using real-time PCR and culture method. Digestion. 2007. 75(4):199-204. [View Abstract]
  3. Zheng HX, Sun Y, Jiang B. [Evaluation of 4 culture methods of Yersinia enterocolitica]. Nan Fang Yi Ke Da Xue Xue Bao. 2007 Sep. 27(9):1438-40. [View Abstract]
  4. Centers for Disease Control and Prevention. Diagnosis and management of foodborne illnesses: a primer for physicians and other health care professionals. MMWR Recomm Rep. 2004 Apr 16. 53:1-33. [View Abstract]
  5. Bottone EJ. Yersinia enterocolitica: a panoramic view of a charismatic microorganism. CRC Crit Rev Microbiol. 1977. 5(2):211-41. [View Abstract]
  6. Schleifstein J, Coleman, MB. An unidentified microorganism resembling B. lignieresi and Pasteurella pseudotuberculosis, pathogenic for man. New York State Journal of Medicine. 1939. 39:1749-53.
  7. Zheng H, Sun Y, Lin S, Mao Z, Jiang B. Yersinia enterocolitica infection in diarrheal patients. Eur J Clin Microbiol Infect Dis. 2008 Aug. 27(8):741-52. [View Abstract]
  8. Huovinen E, Sihvonen LM, Virtanen MJ, Haukka K, Siitonen A, Kuusi M. Symptoms and sources of Yersinia enterocolitica-infection: a case-control study. BMC Infect Dis. 2010 May 20. 10:122. [View Abstract]
  9. Young VB, Falkow S, Schoolnik GK. The invasin protein of Yersinia enterocolitica: internalization of invasin-bearing bacteria by eukaryotic cells is associated with reorganization of the cytoskeleton. J Cell Biol. 1992 Jan. 116(1):197-207. [View Abstract]
  10. Handley SA, Newberry RD, Miller VL. Yersinia enterocolitica invasin-dependent and invasin-independent mechanisms of systemic dissemination. Infect Immun. 2005 Dec. 73(12):8453-5. [View Abstract]
  11. Bradford WD, Noce PS, Gutman LT. Pathologic features of enteric infection with Yersinia enterocolitica. Arch Pathol. 1974 Jul. 98(1):17-22. [View Abstract]
  12. Aho K, Ahvonen P, Lassus A, Sievers K, Tiilikainen A. HL-A 27 in reactive arthritis. A study of Yersinia arthritis and Reiter's disease. Arthritis Rheum. 1974 Sep-Oct. 17(5):521-6. [View Abstract]
  13. Välimäki E, Aittomäki S, Karenko L, Kantonen J, Pettersson T, Turunen U, et al. Normal inflammasome activation and low production of IL-23 by monocyte-derived macrophages from subjects with a history of reactive arthritis. Scand J Rheumatol. 2013 Feb 20. [View Abstract]
  14. Stoddard JJ, Wechsler DS, Nataro JP, Casella JF. Yersinia enterocolitica infection in a patient with sickle cell disease after exposure to chitterlings. Am J Pediatr Hematol Oncol. 1994 May. 16(2):153-5. [View Abstract]
  15. Centers for Disease Control and Prevention. Yersinia enterocolitica gastroenteritis among infants exposed to chitterlings--Chicago, Illinois, 2002. MMWR Morb Mortal Wkly Rep. 2003 Oct 10. 52(40):956-8. [View Abstract]
  16. Notes from the field: Yersinia enterocolitica infections associated with pasteurized milk --- southwestern Pennsylvania, March-August, 2011. MMWR Morb Mortal Wkly Rep. 2011 Oct 21. 60(41):1428. [View Abstract]
  17. Tacket CO, Narain JP, Sattin R, Lofgren JP, Konigsberg C Jr, Rendtorff RC, et al. A multistate outbreak of infections caused by Yersinia enterocolitica transmitted by pasteurized milk. JAMA. 1984 Jan 27. 251(4):483-6. [View Abstract]
  18. Cortes PR, Contreras Funes V, Huerta VG, Dichiara DM. [Yersinia enterocolitica in the fecal material from 6 pediatric patients in the city of Córdoba]. Rev Argent Microbiol. 2010 Jan-Feb. 42(1):79. [View Abstract]
  19. Leclercq A, Martin L, Vergnes ML, Ounnoughene N, Laran JF, Giraud P, et al. Fatal Yersinia enterocolitica biotype 4 serovar O:3 sepsis after red blood cell transfusion. Transfusion. 2005 May. 45(5):814-8. [View Abstract]
  20. Centers for Disease Control and Prevention. Yersinia enterocolitica. CDC. Available at Accessed: Feb 22 2013.
  21. Centers for Disease Control and Prevention. Vital signs: incidence and trends of infection with pathogens transmitted commonly through food--foodborne diseases active surveillance network, 10 U.S. sites, 1996-2010. MMWR Morb Mortal Wkly Rep. 2011 Jun 10. 60(22):749-55. [View Abstract]
  22. Scallan E, Mahon BE, Hoekstra RM, Griffin PM. Estimates of Illnesses, Hospitalizations, and Deaths Caused By Major Bacterial Enteric Pathogens in Young Children in the United States. Pediatr Infect Dis J. 2012 Dec 17. [View Abstract]
  23. Abdel-Haq NM, Asmar BI, Abuhammour WM, Brown WJ. Yersinia enterocolitica infection in children. Pediatr Infect Dis J. 2000 Oct. 19(10):954-8. [View Abstract]
  24. Rosner BM, Stark K, Werber D. Epidemiology of reported Yersinia enterocolitica infections in Germany, 2001-2008. BMC Public Health. 2010 Jun 14. 10:337. [View Abstract]
  25. Saebo A, Vik E, Lange OJ, Matuszkiewicz L. Inflammatory bowel disease associated with Yersinia enterocolitica O:3 infection. Eur J Intern Med. 2005 Jun. 16(3):176-182. [View Abstract]
  26. Ray SM, Ahuja SD, Blake PA, Farley MM, Samuel M, Fiorentino T, et al. Population-based surveillance for Yersinia enterocolitica infections in FoodNet sites, 1996-1999: higher risk of disease in infants and minority populations. Clin Infect Dis. 2004 Apr 15. 38 Suppl 3:S181-9. [View Abstract]
  27. Metchock B, Lonsway DR, Carter GP, Lee LA, McGowan JE Jr. Yersinia enterocolitica: a frequent seasonal stool isolate from children at an urban hospital in the southeast United States. J Clin Microbiol. 1991 Dec. 29(12):2868-9. [View Abstract]
  28. Koehler KM, Lasky T, Fein SB, Delong SM, Hawkins MA, Rabatsky-Ehr T, et al. Population-based incidence of infection with selected bacterial enteric pathogens in children younger than five years of age, 1996-1998. Pediatr Infect Dis J. 2006 Feb. 25(2):129-34. [View Abstract]
  29. Helms M, Simonsen J, Mølbak K. Foodborne bacterial infection and hospitalization: a registry-based study. Clin Infect Dis. 2006 Feb 15. 42(4):498-506. [View Abstract]
  30. Girszyn N, Kerleau JM, Robaday S, Lefebvre S, Marie I, Levesque H. [Pneumonia with bacteremia due to Yersinia enterocolitica in a diabetic patient carrying HLA-B27]. Rev Med Interne. 2007 Dec. 28(12):882-4. [View Abstract]
  31. Hoelen DW, Tjan DH, Schouten MA, Dujardin BC, van Zanten AR. Severe Yersinia enterocolitica sepsis after blood transfusion. Neth J Med. 2007 Sep. 65(8):301-3. [View Abstract]
  32. Pulvirenti D, Aikaterini T, Neri S. Septicemia, hepatic abscess, and encephalitis due to Yersinia enterocolitica. J Clin Gastroenterol. 2007 Mar. 41(3):333-4. [View Abstract]
  33. Jess T, Jess P. Acute terminal ileitis, yersiniosis, and Crohn's disease: a long-term follow-up study of the relationships. Eur J Intern Med. 2001 Apr. 12(2):98-100. [View Abstract]
  34. Navarro-Llavat M, Domènech E, Masnou H, Ojanguren I, Mañosa M, Lorenzo-Zúñiga V, et al. Collagenous duodeno-ileo-colitis with transient IgG deficiency preceded by Yersinia enterocolitica intestinal infection: case report and review of literature. Gastroenterol Hepatol. 2007 Apr. 30(4):219-21. [View Abstract]
  35. Berner R, Kist M, Sauer M. Encephalopathy associated with Yersinia enterocolitica O:3. Lancet. 1998 Feb 7. 351(9100):418. [View Abstract]
  36. von Eckardstein K, Spuler A, Brauer C, Mehl M, Kiwit J. Spontaneous cervical osteomyelitis due to Yersinia enterocolitica in a non-immunocompromised host. Eur J Clin Microbiol Infect Dis. 2004 Jan. 23(1):66-8. [View Abstract]
  37. Krajinovic V, Tambic Andrasevic A, Barsic B. Tricuspidal valve endocarditis due to Yersinia enterocolitica. Infection. 2007 Jun. 35(3):203-5. [View Abstract]
  38. Kelesidis T, Balba G, Worthington M. Axillary abscess in a patient with Yersinia enterocolitica infection as a result of exposure to pork. Am J Med. 2008 Mar. 121(3):e1. [View Abstract]
  39. Mills DM, Meyer DR. Posttraumatic cellulitis and ulcerative conjunctivitis caused by Yersinia enterocolitica O:8. Ophthal Plast Reconstr Surg. 2008 Sep-Oct. 24(5):425-6. [View Abstract]
  40. Tennant SM, Hartland EL, Phumoonna T, Lyras D, Rood JI, Robins-Browne RM, et al. Influence of gastric acid on susceptibility to infection with ingested bacterial pathogens. Infect Immun. 2008 Feb. 76(2):639-45. [View Abstract]
  41. Lamps LW, Madhusudhan KT, Greenson JK, Pierce RH, Massoll NA, Chiles MC, et al. The role of Yersinia enterocolitica and Yersinia pseudotuberculosis in granulomatous appendicitis: a histologic and molecular study. Am J Surg Pathol. 2001 Apr. 25(4):508-15. [View Abstract]
  42. Taccetti G, Trapani S, Ermini M, Falcini F. Reactive arthritis triggered by Yersinia enterocolitica: a review of 18 pediatric cases. Clin Exp Rheumatol. 1994 Nov-Dec. 12(6):681-4. [View Abstract]
  43. De Berardis B, Torresini G, Brucchi M, Marinelli S, Mattucci S, Schietroma M, et al. Yersinia enterocolitica intestinal infection with ileum perforation: report of a clinical observation. Acta Biomed. 2004 Apr. 75(1):77-81. [View Abstract]
  44. Reed RP, Robins-Browne RM, Williams ML. Yersinia enterocolitica peritonitis. Clin Infect Dis. 1997 Dec. 25(6):1468-9. [View Abstract]
  45. Hervás JA, Albertí P, Bregante JI, Boya E, Reina J, Gil J. Chronic intussusception associated with Yersinia enterocolitica mesenteric adenitis. J Pediatr Surg. 1992 Dec. 27(12):1591-2. [View Abstract]
  46. Chandler ND, Parisi MT. Radiological case of the month. Yersinia enterocolitica masquerading as appendicitis. Arch Pediatr Adolesc Med. 1994 May. 148(5):527-8. [View Abstract]
  47. Bottone EJ. Yersinia enterocolitica: the charisma continues. Clin Microbiol Rev. 1997 Apr. 10(2):257-76. [View Abstract]
  48. Vento S, Cainelli F, Cesario F. Infections and thalassaemia. Lancet Infect Dis. 2006 Apr. 6(4):226-33. [View Abstract]
  49. Bergmann TK, Vinding K, Hey H. Multiple hepatic abscesses due to Yersinia enterocolitica infection secondary to primary haemochromatosis. Scand J Gastroenterol. 2001 Aug. 36(8):891-5. [View Abstract]
  50. Antonopoulos P, Constantinidis F, Charalampopoulos G, Dalamarinis K, Karanicas I, Kokkini G. An emergency diagnostic dilemma: a case of Yersinia enterocolitica colitis mimicking acute appendicitis in a beta-thalassemia major patient: the role of CT and literature review. Emerg Radiol. 2008 Mar. 15(2):123-6. [View Abstract]
  51. Renaud N, Lecci L, Courcol RJ, Simonet M, Gaillot O. CHROMagar Yersinia: a new chromogenic agar for the screening of potentially pathogenic Yersinia enterocolitica in stools. J Clin Microbiol. 2013 Jan 30. [View Abstract]
  52. You Y, Fu C, Zeng X, Fang D, Yan X, Sun B, et al. A novel DNA microarray for rapid diagnosis of enteropathogenic bacteria in stool specimens of patients with diarrhea. J Microbiol Methods. 2008 Dec. 75(3):566-71. [View Abstract]
  53. Kojima M, Morita Y, Shimizu K, Yoshida T, Yamada I, Togo T, et al. Immunohistological findings of suppurative granulomas of Yersinia enterocolitica appendicitis: a report of two cases. Pathol Res Pract. 2007. 203(2):115-9. [View Abstract]
  54. Noble RC. Failure of cefotaxime in the treatment of Yersinia enterocolitica sepsis despite in vitro susceptibility. Current Therapeutic Research, Clinical and Experimental. 1989. 46(4):692-4.
  55. Lal M, Kaur H, Gupta LK. Y.enterocolitica gastroenteritis - A prospective study. Indian J Med Microbiol. 2003 Jul-Sep. 21(3):186-8. [View Abstract]
  56. Chan J, Gandhi RT. A Case of Septic Arthritis of the Shoulder Due to Yersinia enterocolitica with Review of the Literature. Open Forum Infect Dis. 2014 Sep. 1 (2):ofu054. [View Abstract]

Gram stain of Yersinia enterocolitica.

Yersinia enterocolitis in a 45-year-old white woman who presented with chronic diarrhea.

Gram stain of Yersinia enterocolitica.

Yersinia enterocolitis in a 45-year-old white woman who presented with chronic diarrhea.

Yersinia enterocolitis in a 45-year-old white woman who presented with chronic diarrhea.

Gram stain of Yersinia enterocolitica.